Skip to main content
OpenTrials
Completed

NCT Number: NCT03056534

R3 Delta Ceramic Acetabular System PAS U.S.

R3 Delta Post-Approval Study U.S.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Degenerative Joint Disease Joint Diseases Musculoskeletal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Foundation for Orthopaedic Research and Education, Tampa, Florida, United States

Loading trial locations.

About this study

Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - US The R3 Ceramic Acetabular System is indicated for use in skeletally mature patients requiring primary total hip arthroplasty due to non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, avascular necrosis, or traumatic arthritis. The expected timeline for the study is a total of approximately 5 years: 6 months for site initiation, 12 months for subject enrollment, 3 years until the last subject enrolled has reached the 3 year follow-up interval.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is 18-75 years old and he/she is skeletally mature
  • Patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (degenerative joint disease) such as osteoarthritis, avascular necrosis, or traumatic arthritis.
  • Patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk
  • Patient is willing and able to participate in required follow-up visits and to complete study procedures and questionnaires
  • Patient has consented to participating in the study by signing the IRB/EC approved informed consent form

Exclusion criteria

  • Patients with insufficient quantity or quality of bone support; metabolic bone disease; osteoporosis
  • Patients with neurological or muscular conditions that would place extreme load or instability upon the hip joint
  • Patients with active joint infections or chronic systemic infection
  • Obese patients where obesity is defined as BMI ≥ 40
  • Skeletal immaturity
  • Known allergy to implant materials

Treatment and study plan

R3 Biolox Delta Ceramic Acetabular System

Device

All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).

Primary outcomes

  1. Overall Study Success at 3 Years Postoperative

    Time frame: 3 Years Postoperative

    Number of participants with overall study success were identified as "Success" or "Failure" where success indicated all the following:

    • No component revision for any reason
    • Modified Harris Hip Score (mHHS) greater than or equal to 80 points
    • No radiographic failure (Radiographic failure was defined as no radiolucencies greater than 2 millimeters (mm) in 50% or more in any of the cup or stem zones, no femoral or acetabular subsidence greater than or equal to 5 mm from baseline, and no acetabular cup inclination changes greater than 4 degrees from baseline when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" mHHS pain score.)

  2. Component Revisions at 3 Years Postoperative

    Time frame: 3 Years Postoperative

    Number of participants component revisions identified as "Success" or "Failure" with success defined as no component revision for any reason.

  3. Number of Participants With Modified Harris Hip Score Greater Than or Equal to 80 Points

    Time frame: 3 Years postoperative

    The Harris Hip Score (HHS) is a joint specific score that consists of 10 items covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. The modified Harris Hip Score (mHHS) includes all the same domains as the HHS except for the hip range of motion. Total mHHS scale ranges from 0 (worst) to 95 (best). The number of participants were identified as "Success" or "Failure" with success defined as a mHHS that is greater than or equal to 80 points.

  4. Overall Radiographic Success at 3 Years Postoperative

    Time frame: 3 Years Postoperative

    Number of participants with overall radiographic success identified as "Success" or "Failure" where success indicated all of the following:

    • No radiolucencies greater than 2 millimeters (mm) in 50% or more in any of the cup or stem zones
    • No femoral or acetabular subsidence greater than or equal to 5 mm from baseline
    • No acetabular cup inclination changes greater than 4 degrees from baseline when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" mHHS pain score

  5. Number of Participants With Absence of Radiolucency at 3 Years Postoperative

    Time frame: 3 Years postoperative

    Number of participants identified as "Success" or "Failure" with success defined as no radiolucencies greater than 2 millimeters (mm) in 50% or more in any of the cup or stem zones

  6. Number of Participants With Absence of Femoral Subsidence or Acetabular Migration at 3 Years Postoperative

    Time frame: 3 Years postoperative

    Number of participants identified as "Success" or "Failure" with success defined as no femoral subsidence or acetabular migration greater than or equal to 5 millimeters (mm) from baseline.

  7. Number of Participants With Absence of Acetabular Cup Inclination Changes Greater Than 4 Degrees From Baseline at 3 Years Postoperative

    Time frame: 3 Years postoperative

    Number of participants identified as "Success" or "Failure" with success defined as no acetabular cup inclination changes greater than 4 degrees from baseline when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" mHHS pain score.

Secondary outcomes

  1. Modified Hip Harris Score (mHHS)

    Time frame: Preoperative, 3 months, 1 year, 2 years, 3 years

    The Harris Hip Score (HHS) is a joint specific score that consists of 10 items covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. The modified Harris Hip Score (mHHS) includes all the same domains as the HHS except for the hip range of motion. Total mHHS scale ranges from 0 (worst) to 95 (best).

  2. Radiographic Findings: Number of Participants With Absence of Radiolucency

    Time frame: 3 months, 1 year, 2 years

    The number of participants identified as either "Success" or "Failure" with success defined as no radiolucencies greater than 2 millimeters (mm) in 50% or more in any of the cup or stem zones when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" pain modified Harris Hip Score (mHHS).

  3. Radiographic Findings: Number of Participants With Absence of Femoral Subsidence or Acetabular Migration

    Time frame: 3 months, 1 year, 2 years

    The number of participants identified as either "Success" or "Failure" with success defined as no femoral subsidence or acetabular migration greater than or equal to 5 millimeters (mm) from baseline when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" pain modified Harris Hip Score (mHHS).

  4. Radiographic Findings: Number of Participants With Absence of Acetabular Cup Inclination Changes

    Time frame: 3 months, 1 year, and 2 years

    Number of participants identified as "Success" or "Failure" with success defined as no acetabular cup inclination changes greater than 4 degrees from baseline when accompanied by a "Mild", "Moderate", "Marked" or "Disabled" pain modified Harris Hip Score (mHHS).

  5. Implant Survivorship Kaplan-Meier Estimate

    Time frame: Postoperatively, up to 3 years

    The Kaplan-Meier estimate of implant survivorship was measured from date of surgery to date of final visit with survival defined as no revision for any reason. A revision indicated reoperation was needed where any component (acetabular cup, acetabular liner, femoral head, or femoral stem) was replaced.

Sponsors and collaborators

Lead sponsor

Smith & Nephew, Inc.

Industry

Registry information

Official study title

Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - US

Acronym: R3-PAS

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Feb 17, 2017
Registry last updated
Apr 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.